Indications and Usage

Carfilzomib is indicated in combination with

• Lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. It is also indicated as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.

In a clinical study of relapsed multiple myeloma, carfilzomib and dexamethasone kept the disease from getting worse longer than bortezomib and dexamethasone (median of 18.7 months compared with 9.4 months) and helped patients live longer (median of 47.6 months compared with 40 months).

• Daratumumab (Darzalex®) plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy.

Side effects needing medical attention

Fatigue; anemia; nausea; low platelet counts; breathlessness; diarrhea; fever;  cardiac arrest and other cardiac failure events; pulmonary hypertension; pulmonary complications; liver damage and liver failure; infusion reactions including fever, chills, joint pain, muscle pain, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, fainting, chest tightness, chest pain.  

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.